LamKap Bio gamma AG is a biotechnology company that researches, develops, manufactures and tests fully human bispecific antibodies for cancer immunotherapy, particularly for solid tumors. Its molecules are designed to redirect immune effector cells (macrophages, T cells, natural killer cells) to attack tumor cells and include programs targeting CD47, CD3, CD28 and tumor-associated antigens such as CEA and GPC3.
AI-generated
Offering
Products & services
Industry:Research & Development
✓ Offered
Outbound Leads by COHAGA
Looking for direct email addresses and phone numbers?
Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.
Research, development and manufacture of bispecific antibodies
Research, development and manufacture of bispecific antibodies for the treatment of malignant tumours; targeted at T cells, macrophages and natural killer cells.
Knowledge
No knowledge articles yet
Once LamKap Bio gamma AG has claimed this profile, we'll publish editorial articles and case studies here together.